Agenda
For detail Talk Descriptions, click here.

The 2007 National Conference on Prostate Cancer
State of the Art Treatments:
Making a Positive Impact on Quality of Life

Marriott Hotel Los Angeles Airport, California

September 7, 2007

Friday Morning: Registration and Welcome

10:00 Registration

Friday Afternoon: Getting a Perspective

1:00 Welcome Remarks
Chester Swenson
Board President, Prostate Cancer Research Institute
Moderator: Duke Bahn, M.D.
Medical Director, Prostate Institute of America

1:15 Color Doppler Biopsy Demonstration - talk description
Duke K. Bahn, M.D.
Medical Director, Prostate Institute of America
Fred Lee, M.D.
Clinical Professor of Radiology
Wayne State University

2:45 Break

3:00 Prostate Pathology - talk description
David G. Bostwick, M.D., M.B.A.
CEO & Medical Director, Bostwick Laboratories

3:45 Staging, Risk Management, and Active Surveillance - talk description
Mark C. Scholz, M.D.
Medical Director, Prostate Oncology Specialists, Inc.

4:30 Navigating Medicare - talk description
Arthur N. Lurvey, M.D.
Medicare Contractor Medical Director
National Government Services, Inc.

5:00 End of Program

September 8, 2007

Saturday Morning: Prostate Cancer Essentials

8:20 Announcements
Moderator: Donald S. Coffey, Ph.D.
Professor of Urology, Oncology, Pharmacology and
Molecular Sciences, Pathology
Department of Urology, Johns Hopkins University
School of Medicine

8:30 Minimizing Prostate Cancer through Diet - talk description
Colin Campbell, Ph.D.
Emeritus Professor of Nutritional Sciences Cornell University, Ithaca NY

9:15 Magnetic Resonance Imaging - talk description
Combidex, Spectroscopy, & Bone marrow imaging
John Kurhanewicz, Ph.D.
Professor of Radiology and Pharmaceutical Chemistry,
University of California, San Francisco

10:00 Break

10:30 Impact of Supplements - talk description
Lycopene, Selenium, Vitamin E & D, Zyflamend,
Curcumin, MCP, Pomegranate
Charles “Snuffy” Myers, M.D.
Director, American Institute for Diseases of the Prostate

11:15 Low-Impact Pharmaceuticals - talk description
Avodart, Calcitriol, Avandia, Atacand, Celebrex
Stephen B. Strum, M.D.
Medical Oncologist

12:00 Lunch and Support Group Meetings

Saturday Afternoon: Intermediate Risk Disease

1:30 Robotic Surgery - talk description
Mark H. Kawachi, M.D., F.A.C.S.
Associate Professor, Urologic Surgical Oncology
Director, Prostate Cancer Center

2:15 IMRT/Brachytherapy (Radioactive Seeds) - talk description
Christopher M. Rose, M.D.
Chief Technology Officer, Vantage Oncology
Medical Director, Center for Radiation Therapy, Beverly Hills

3:00 Break

3:30 Focal Cryotherapy - talk description
Duke K. Bahn, M.D.
Medical Director, Prostate Institute of America

4:00 Primary Intermittent Testosterone Deprivation - talk description
& supportive care with Aranesp & Zometa
Stephen B. Strum, M.D.
Medical Oncologist

5:00 End of Program

Gala Dinner: Technology in Revolution - talk description

Donald S. Coffey, Ph.D.
Professor of Urology, Oncology, Pharmacology and
Molecular Sciences, Pathology
Department of Urology, Johns Hopkins University School of
Medicine

September 9, 2007

Sunday Morning: Management of Aggressive Prostate Cancer

8:20 Announcements
Moderator: Mark Scholz M.D.
Executive Director Prostate Cancer Research Institute

8:30 Cardiac Issues for Prostate Cancer Patients - talk description
Matthew J. Budoff, M.D.
Program Director, Division of Cardiology,
Harbor-UCLA Medical Center

9:00 Adjuvant Chemotherapy and Taxotere Combinations - talk description
Avastin, DN-101, Samarium, Neulasta, Aranesp
Richard Y. Lam, M.D.
Research Director, Prostate Oncology Specialists, Inc.

9:45 IMRT for Oligo-metastasis and Lymph nodes - talk description
Christopher M. Rose, M.D.
Chief Technology Officer, Vantage Oncology
Medical Director, Center for Radiation Therapy, Beverly Hills

10:15 Break

10:30 Oral Agents:
Satraplatin, Thalidomide, (Revlimid), Nilutamide,
Phenylbutarate, Estrogens, Ketoconazole - talk description
Charles “Snuffy” Myers, M.D.
Director, American Institute for Diseases of the Prostate

11:15 Harnessing the Immune system:
Leukine®, anti-CTLA4, Dendritic cells, Low dose cyclophosphamide - talk description
William Cavanagh
Chief Scientific Officer
Sangretech Biomedical

12:00 Lunch and Support Group Meetings

Sunday Afternoon: What’s in Store for the Future

1:30 Exciting New Agents in the Research Pipeline - talk description
Howard Soule, Ph.D.
Executive Vice President, Discovery and Translation,
Prostate Cancer Foundation

2:15 Break

2:30 Multi-Disciplinary Round Table with Case
Presentations and Questions from the Audience - talk description
Duke Bahn, Stan Brosman, Bill Cavanagh, Richard Lam,
Snuffy Myers, Chris Rose, Mark Scholz, Stephen Strum
Treatments to be Discussed: Zometa, Samarium, Avastin,
Thalidomide, Taxotere, Revlimid, Taxol, Carboplatin,
Abraxane, Dendritic Cells, Neulasta, Growth Factorm
Inhibitors, Satraplatin, Aranesp, Others

5:00 End of Program

 

 

Prostate Cancer Research Institute (PCRI)

Material provided by PCRI is intended for educational purposes for discussion with your physician and should not be considered as medical advice. Information and opinions expressed on this website are not an endorsement by PCRI for any treatment, product or service.